Navigation Links
Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

93 Percent of Nucleoside-Naive Chronic Hepatitis B e-Antigen (HBeAg)-Negative Patients Achieved Undetectable Viral Load by Week 48 of Re-Treatment

PRINCETON, N.J., April 13, 2007 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today announced data from a cohort of nucleoside-naive HBeAg-negative chronic hepatitis B patients (ETV-027/901, n=99). These data showed that patients who experienced recurrent levels of hepatitis B virus in the blood after interruption of treatment with BARACLUDE(R) (entecavir) achieved viral suppression and liver enzyme (ALT) normalization when re- treated for 48 weeks with BARACLUDE. The study results were presented at the 42nd Annual Meeting of the European Association for the Study of Liver Diseases (EASL) in Barcelona, Spain.

In this cohort, 93 percent of patients who were re-treated with BARACLUDE had undetectable viral load - the level of the hepatitis B virus in the blood - (HBV DNA <300 copies/mL, measured by a common assay - polymerase chain reaction or PCR) and 83 percent achieved liver enzyme normalization (ALT less than or equal to 1xULN) after 48 weeks of therapy.

"This study showed that when treated again with BARACLUDE for 48 weeks, patients achieved responses similar to those seen prior to treatment interruption, with safety results consistent with previously reported experience," said Hakan Senturk, MD, of the Ist.Univ.Cerrahpasa Tip Fak, Istanbul, Turkey.

No deaths or treatment discontinuations due to adverse events were reported in this cohort. The most common adverse events occurring in greater than 10 percent of patients were abdominal pain, fatigue, upper respiratory tract infection, nasopharyngitis, increased ALT, arthralgia, and headache.

About the Nucleoside-Naive HBeAg-Negative BARACLUDE(R) (entecavir) Re- Treatment Cohort

This analysis evaluated BARACLUDE(R) (entecavir) in nucleoside-naive chronic HBeAg-negative patie
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
2. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
3. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
9. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
10. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
Post Your Comments:
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 ... Market Outlook to 2020″, provides key ... General Surgery devices market. The report ... dollars, and volume (in units) within ... Cystoscopes, Colonoscopes, Sigmoidoscopes, Esophagoscopes & Gastroscopes, ...
(Date:9/19/2014)... 2014 According to the ... Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications ... - Global Forecast to 2019" published by MarketsandMarkets, the ... $19,786.3 Million by 2019 from $14,240.0 Million in ... to 2019. Browse 74 market data ...
(Date:9/19/2014)... , Sept. 19, 2014 Merck (NYSE: MRK ... and Canada , is teaming with celebrity ... Diabetes: Logra Tus Metas , an educational program encouraging Hispanics with ... -- a key treatment goal to help reduce the risk of ... are at a higher risk for developing type 2 diabetes ...
Breaking Medicine Technology:United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5
... the Journal of Clinical Oncology -, NEW YORK, ... II study - which will be published in ... Clinical Oncology (JCO) and are now,available as an ... - demonstrate that,ixabepilone, a Bristol-Myers Squibb Company investigational,compound, ...
... WIRE) -- July 06, 2007 ... target="_blank" href=,'http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB"%3EDORB'>,http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB">DORB ),("DOR" or the ... European Patent,Office has granted a ... claims related to,oral vaccination using ...
Cached Medicine Technology:Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 2Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 3Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 4DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 6
(Date:9/20/2014)... 2014 The print component of ... of the Calgary Herald, with a circulation of ... 270,000. The digital component is distributed nationally through ... network of top news sites and partner outlets. ... visit http://www.worklifebalanceinfo.ca . , The publication features ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 The festival season ... busy selling its newly released luxurious cocktail dresses . ... company has recently decided to launch a new promotion for ... is offered with a discounted price, from 20 to 71 ... a wide range of choices. They are provided in many ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 iFitDress.com, the ... gowns for women, has recently unveiled its new collection ... big sale for special offer on these new outfits; ... shopping season. All customers can now buy cheap ... The company’s sales representative says, “We have extensive experience ...
(Date:9/20/2014)... September 20, 2014 "As a nurse, patients ... tanks," said an inventor from Tamaqua, Pa. "The reason that ... the backs of their chairs. My invention enables them to ... Kam Oxygen Sensor to make it easier to monitor the ... user knows when the tank is low. It allows changeovers ...
(Date:9/20/2014)... September 20, 2014 QueenBeeTickets.com is ready ... star’s tour performances. She will visit many cities in ... until the 16th of April. , Click Here ... Tour tickets at QueenBeeTickets.com. , The star’s fans are ... see their favorite young singer in a live performance. ...
Breaking Medicine News(10 mins):Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Fashionable Cocktail Dresses Unveiled Online at iFitDress.com 2Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2
... of an initiative to give back to the cancer ... meetings, the American Society for Radiation Oncology (ASTRO) is ... of cancer survivorship issues., Gilda,s Club South Florida will ... exhibit at ASTRO,s 53rd Annual Meeting, scheduled for October ...
... (Sept. 1, 2011) Patients often take drugs to ... develop ulcers from taking their anti-inflammatory drugs for conditions ... major problems for their small intestines, McMaster researchers have ... Digestive Health Research Institute has found those stomach acid-reducing ...
... THURSDAY, Sept. 1 (HealthDay News) -- Strokes are on ... report shows. The number of people aged 15 to ... 1995 and 2008, say researchers from the U.S. Centers for ... to the increasing numbers of young people who have diseases ...
... with ALK-rearranged non-small cell lung cancer (NSCLC) responded ... patients whose cancer did not show ALK translocation, ... of the Journal of Thoracic Oncology, the official ... of Lung Cancer (IASLC). Lung adenocarcinoma can ...
... researchers have successfully injected cultured red blood cells (cRBCs) created ... according to study results published today in ... Society of Hematology (ASH). As the global need for ... is decreasing, these study results provide hope that one day ...
... Sept. 1 (HealthDay News) -- Researchers report that they used ... successfully injected the blood cells back into the human donor ... The findings raise the possibility of creating individualized blood supplies ... they need a transfusion, a potentially dicey situation if someone ...
Cached Medicine News:Health News:Strokes Rising Among Teens, Young Adults: CDC 2Health News:Strokes Rising Among Teens, Young Adults: CDC 3Health News:Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows 2Health News:Researchers successfully perform first injection of cultured red blood cells in human donor 2Health News:Scientists Use Stem Cells for Blood 'Self-Transfusion' 2
Silver Aluminum finish, full view tempered bent glass sides and door 2 sliding glass doors with push bottom lock and 4 adjustable shelves. Pearwood MDF roof and base. Roof with 3 50 watt recessed hal...
Two sided, 72 frame, acrylic eyewear tower with side mirrors and sign holder on top. Breaks down for easy shipping....
1 Frame clear base post with transparent Eyevee 2.0 Clip....
Omni labs carries an extensive line of frames, lenses, soft contacts, RGP lenses, and many other products and services. It supports Zeiss, American optical, Sola, Rodenstock, Zylowear, Eyewear design...
Medicine Products: